arrow
R

Raúl Córdoba

fundación jiménez díaz university hospital and health research institute iis-fjd
H指数:36
被引数:7,403

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Mapping the capacity for geriatric blood Cancer Care in Latin America: A cross-sectional survey of current status and future priorities

绘制拉丁美洲老年血液癌症护理能力地图:一项关于当前状况和未来优先事项的横断面调查

2026-07-010
PRE
Underrated, Unvaccinated, Untreated: A Multinational Registry Analysis of Hmpv in Haematological Malignancy, Insights From EpiCOVIDeha/Epiresha Registry

被低估、未接种疫苗、未治疗:一项关于血液系统恶性肿瘤患者Hmpv的多国登记分析,来自EpiCOVIDeha/Epiresha登记研究的见解

2026-02-270
OA
Assessing Overall Survival Benefits in Advanced Cancers: The Role of External Comparator Cohort Studies with Real-World Data

评估晚期癌症总生存获益:外部对照队列研究结合真实世界数据的作用

2026-02-110
OAAI
CCL18: a potential immunosuppressive biomarker for prognosis in ABC diffuse large B-cell lymphoma

CCL18:一种ABC型弥漫大B细胞淋巴瘤预后中潜在的免疫抑制生物标志物

2025-12-150
OAAI
Beyond the Usual Suspects: RSV Infection in Patients With Hematological Malignancies Compared to Influenza and SARS-COV-2-A Report From the EPICOVIDEHA/EPIRESEHA Registry
2025-12-010
OAAI
Laboratory Prognostic Index (LAB-PI) in diffuse large B-cell lymphoma: a single blood analysis predicts outcomes as good as IPI, NCCN-IPI, and GELTAMO-IPI☆

弥漫大B细胞淋巴瘤中的实验室预后指数(LAB-PI):单一血液分析预测结果与IPI、NCCN-IPI和GELTAMO-IPI相当☆

2025-11-250
OAAI
Effects of an Electronic Patient Reported Outcome Measures (e-PROMs) Program on Symptom Reporting, Use of Healthcare, and Overall Survival in Patients With Lymphoma: A Multicenter Prospective Study

电子患者报告结局测量(e-PROMs)项目对淋巴瘤患者症状报告、医疗资源利用及总生存期的影响:一项多中心前瞻性研究

2025-10-010
OAAI
Epcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trial

Epcoritamab联合GemOx在移植不合格的复发/难治性DLBCL中的应用:EPCORE NHL-2试验的结果

BLOOD
IF23.1
2025-01-103
OA
Respiratory Viruses in Patients With Hematological Malignancy in Boreal Autumn/Winter 2023-2024: EPICOVIDEHA-EPIFLUEHA Report
2024-12-230
OAAI
Immunotherapy May be Preferable to Chemotherapy As Second-Line Treatment for POD24 Follicular Lymphoma (FL) Patients

免疫疗法可能比化疗更适合作为POD24滤泡性淋巴瘤(FL)患者的二线治疗方案。

BLOOD
IF23.1
2024-11-050
PRE
Evolution of Treatment Patterns and Sequencing in Mantle Cell Lymphoma (MCL) in Spain and Their Impact on Survival. the Geltamo-MCL-2022 Study

西班牙套细胞淋巴瘤(MCL)治疗模式与治疗顺序的演变及其对生存的影响:Geltamo-MCL-2022研究

BLOOD
IF23.1
2024-11-050
PRE
The Role of Comprehensive Geriatric Assessment in Newly Diagnosed Multiple Myeloma Elderly Patients: Analysis of Single Spanish Institution

综合老年评估在 newly diagnosed multiple myeloma elderly patients 中的作用:单一西班牙机构分析

BLOOD
IF23.1
2024-11-050
PRE
Preliminary Results from an Ongoing Phase 2, Open-Label, Multicenter, Single-Arm Study Assessing an Every-4-Week Dosing Schedule of Mogamulizumab in Patients with Cutaneous T-Cell Lymphoma
2024-10-010
PRE
Cardiovascular Considerations Before Cancer Therapy Gaps in Evidence and JACC: CardioOncology Expert Panel Recommendations

癌症治疗前的心血管注意事项证据和JACC的差距: 心脏肿瘤学专家小组的建议

2024-10-011
OA
Rationale and design of RESILIENCE: A prospective randomized clinical trial evaluating remote ischaemic conditioning for the prevention of anthracycline cardiotoxicity

弹性的基本原理和设计: 一项前瞻性随机临床试验,评估远程缺血调节预防蒽环类药物心脏毒性

2024-08-302
OA